Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
monoclonal antibodies
Biotech
Genmab buys 2nd antibody from Scancell in deal worth up to $630M
Scancell can earn up to $630 million from the new sale if Genmab spins the antibody into drug products across all defined modalities.
Darren Incorvaia
Dec 4, 2024 11:55am
Roivant’s midstage asset fails to show benefit in lung disease
Dec 3, 2024 10:32am
Alector lays off 17% of staff after ph. 2 Alzheimer's drug fail
Nov 26, 2024 4:50am
Lilly taps Oblique for new angle on high-value antibody target
Aug 22, 2024 9:13am
Merck’s mAB prevents RSV in infants, teeing up talks with FDA
Jul 23, 2024 8:18am
Takeda's anti-CD38 antibody boosts platelet count in phase 2
Jun 24, 2024 8:58am